- Home
- CHRN vs ATAI Comparison
CHRN vs ATAI Comparison
Compare CHRN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRN | ATAI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CHRN | ATAI |
|---|---|---|
| Price | $21.06 | $7.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 148.6K | ★ 6.9M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $15.74 | $3.27 |
| 52 Week High | $30.00 | $7.45 |
Technical Indicators
Market Signals| Indicator | CHRN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 65.62 |
| Support Level | $19.36 | $3.32 |
| Resistance Level | $24.97 | N/A |
| Average True Range (ATR) | 2.14 | 0.08 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 53.83 | 52.78 |
Price Performance
Historical ComparisonAbout CHRN ChronoScale Corporation Common Stock
ChronoScale Corp is focused on providing computing infrastructure for artificial intelligence workloads. It offers GPU-based infrastructure for AI training, inference, and high-performance computing.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.